Qingxin Yu

447 total citations · 1 hit paper
30 papers, 247 citations indexed

About

Qingxin Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Qingxin Yu has authored 30 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Qingxin Yu's work include Epigenetics and DNA Methylation (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Ferroptosis and cancer prognosis (5 papers). Qingxin Yu is often cited by papers focused on Epigenetics and DNA Methylation (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Ferroptosis and cancer prognosis (5 papers). Qingxin Yu collaborates with scholars based in China, United Kingdom and United States. Qingxin Yu's co-authors include Dengxiong Li, Dechao Feng, Wuran Wei, Luxia Ye, Zhouting Tuo, Ruicheng Wu, Koo Han Yoo, William C. Cho, Facai Zhang and Shi Deng and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Advanced Science.

In The Last Decade

Qingxin Yu

27 papers receiving 247 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies

2025 16 citations Qingxin Yu, Luxia Ye et al. profile →

Peers

Countries citing papers authored by Qingxin Yu

Since Specialization

Citations

This map shows the geographic impact of Qingxin Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingxin Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingxin Yu more than expected).

Fields of papers citing papers by Qingxin Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingxin Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingxin Yu. The network helps show where Qingxin Yu may publish in the future.

Co-authorship network of co-authors of Qingxin Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Qingxin Yu. A scholar is included among the top collaborators of Qingxin Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingxin Yu. Qingxin Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tracing the Evolution of Sex Hormones and Receptor‐Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease 2025 ·Advanced Science ·Dengxiong Li, Zhipeng Wang, Qingxin Yu, Jie Wang, Ruicheng Wu, Zhouting Tuo, Koo Han Yoo, (unknown), Luxia Ye, (unknown), (unknown), (unknown), (unknown), (unknown), William C. Cho, Wuran Wei, (unknown)	4
2	Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance 2025 ·Journal of Pharmaceutical Analysis ·Zhipeng Wang, Jie Wang, (unknown), (unknown), (unknown), Luxia Ye, Zhouting Tuo, Qingxin Yu, (unknown), (unknown), William C. Cho, Siang‐Boon Koh, Wei Xiong, Dechao Feng	5
3	Interactions between radiotherapy resistance mechanisms and the tumor microenvironment 2025 ·Critical Reviews in Oncology/Hematology ·Dengxiong Li, Jie Wang, Xinrui Li, Zhipeng Wang, Qingxin Yu, Siang‐Boon Koh, (unknown), Luxia Ye, (unknown), (unknown), (unknown), (unknown), Wuran Wei, Koo Han Yoo, William C. Cho, Dechao Feng, Susan Heavey	1
4	SLC39A14 promotes the development of esophageal squamous cell carcinoma through PI3K/Akt/mTOR signaling pathway 2024 ·International Immunopharmacology ·(unknown), Qingxin Yu, Luxia Ye, (unknown)	3
5	Basic helix–loop–helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases 2024 ·Burns & Trauma ·(unknown), Zhipeng Wang, Luxia Ye, Ruicheng Wu, Jie Wang, Qingxin Yu, (unknown), Zhouting Tuo, Koo Han Yoo, (unknown), Wuran Wei, Dengxiong Li, William C. Cho, Zhihong Liu, Dechao Feng	7
6	Efficiency of transurethral en‐bloc resection vs. conventional transurethral resection for non‐muscle‐invasive bladder cancer: An umbrella review 2024 ·Cancer Medicine ·Dengxiong Li, Qingxin Yu, Ruicheng Wu, Jie Wang, Dechao Feng, Shi Deng	9
7	The impact protection behavior of UHPC composite structure on RC columns 2024 ·Case Studies in Construction Materials ·(unknown), (unknown), Qingxin Yu, (unknown), Yong Huang, Quansheng Sun	3
8	Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review 2024 ·Pharmacological Research ·Zhouting Tuo, Ying Zhang, (unknown), (unknown), (unknown), Jie Wang, Qingxin Yu, Luxia Ye, (unknown), (unknown), Yubo Yang, Koo Han Yoo, (unknown), (unknown), William C. Cho, Susan Heavey, Wuran Wei, Dechao Feng	8
9	GREM1 may be a biological indicator and potential target of bladder cancer 2024 ·Scientific Reports ·Qingxin Yu, (unknown), (unknown), Luxia Ye, Haihong Zheng, (unknown)	3
10	Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives 2024 ·Chinese Journal of Cancer Research ·Dengxiong Li, (unknown), Qingxin Yu, Zhouting Tuo, Jie Wang, Koo Han Yoo, Wuran Wei, Yubo Yang, Luxia Ye, Yiqing Guo, (unknown), (unknown), Toryn Poolman, Jeremy P. Burton, William C. Cho, Susan Heavey, Dechao Feng	7
11	Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives 2024 ·Redox Biology ·Dengxiong Li, Qingxin Yu, (unknown), Zhouting Tuo, Jie Wang, Luxia Ye, (unknown), (unknown), Koo Han Yoo, Wuran Wei, (unknown), Shi Deng, (unknown), William C. Cho, Susan Heavey, Dechao Feng	40
12	Advancements and challenges of R-loops in cancers: Biological insights and future directions 2024 ·Cancer Letters ·Dengxiong Li, (unknown), Xinrui Li, Qingxin Yu, Ruicheng Wu, Jie Wang, Zhipeng Wang, (unknown), Luxia Ye, (unknown), Zhouting Tuo, Wuran Wei, Koo Han Yoo, William C. Cho, Dechao Feng	9
13	A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non–Muscle-Invasive Bladder Cancer 2024 ·Clinical Genitourinary Cancer ·Dengxiong Li, Ruicheng Wu, Jie Wang, (unknown), Qingxin Yu, Dechao Feng, (unknown)	2
14	Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF) 2024 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·(unknown), Zhouting Tuo, (unknown), Ruicheng Wu, Jie Wang, Qingxin Yu, (unknown), Akira Miyamoto, Koo Han Yoo, (unknown), Wuran Wei, (unknown), Dechao Feng	6
15	Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions 2024 ·Aging and Disease ·Dengxiong Li, Qingxin Yu, Ruicheng Wu, Zhouting Tuo, (unknown), Jie Wang, (unknown), Luxia Ye, Xing Ye, Koo Han Yoo, (unknown), (unknown), Wuran Wei, Dechao Feng	10
16	FRICTION TEST AND PARAMETER ANALYSIS OF PRESTRESSED CONCRETE CONTINUOUS BEAM BRIDGE 2023 ·Stavební obzor ·Qingxin Yu, Quansheng Sun, (unknown)	0
17	By Increasing the Expression and Activation of STAT3, Sustained C5a Stimulation Increases the Proliferation, Migration, and Invasion of RCC Cells and Promotes the Growth of Transgrafted Tumors 2021 ·Cancer Management and Research ·Jing‐Min Zheng, (unknown), Hongyuan Yu, (unknown), Qingxin Yu, (unknown), (unknown)	3
18	The Significance of INHBE Expression in the Cancer Cells of Clear-Cell Renal Cell Carcinoma 2021 ·Urologia Internationalis ·Zi-Bin Xu, Meifu Gan, Hongyuan Yu, (unknown), (unknown), Qingxin Yu, Jing‐Min Zheng	5
19	KDF1, a Novel Tumor Suppressor in Clear Cell Renal Cell Carcinoma 2021 ·Frontiers in Oncology ·Jing‐Min Zheng, Meifu Gan, Hongyuan Yu, Luxia Ye, Qingxin Yu, (unknown), (unknown), (unknown), (unknown)	11
20	What Motivates Chinese Young Adults to Use mHealth? 2019 ·Healthcare ·Wai Ming To, Peter K.C. Lee, (unknown), Junhao Wang, Yang Yihan, Qingxin Yu	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact